Under Priority Review status, the FDA accepts Bristol-Myers Squibb’s (NYSE:BMY)
marketing application for lisocabtagene maraleucel (liso-cel), its
autologous anti-CD19 chimeric antigen receptor (CAR) T-cell
immunotherapy with a defined composition of purified CD8+ and CD4+ CAR T
cells for the treatment of adult patients with relapsed or refractory
large B-cell lymphoma who have received at least two prior lines of
therapy.
The agency’s action date is August 17.
Holders of BMY Contingent Value Rights (CVR) (NYSE:BMY.RT) may see a rally today. Yesterday’s close was $3.36.
https://seekingalpha.com/news/3541632-bristol-myers-squibbs-liso-cel-fast-tracked-in-u-s-for-large-b-cell-lymphoma
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.